Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis

Indian Journal of Rheumatology

Volumn 3, Issue 3 SUPPLEMENT, 2008, Pages

  Misra, R ^a   Sharma, B L ^b   Gupta, R ^c   Pandya, S ^d   Agarwal, S ^e   Agarwal, P ^f   Grover, S ^g   Sarma, P ^h   Wangjam, K ⁱ  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b Jaipur Hospital   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d Vedanta Institute of Medical Sciences   (India)

^e NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^f DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^g SWAMI VIVEKANAND SUBHARTI UNIVERSITY   (India)

^h Institute of Neurological Sciences   (India)

ⁱ REGIONAL INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANALGESIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOSPORIN; DEFLAZACORT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROCHLORPERAZINE; PROTON PUMP INHIBITOR; RANITIDINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ANTIBODY; VITAMIN D;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADRENAL CORTEX INSUFFICIENCY; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BLOOD ANALYSIS; CARDIOTOXICITY; CLEFT LIP; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DEPIGMENTATION; DIABETES MELLITUS; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; ELDERLY CARE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FETAL HEMORRHAGE; FETUS MALFORMATION; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; GASTROSCHISIS; GINGIVA HYPERTROPHY; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INTRAUTERINE GROWTH RETARDATION; KIDNEY DISEASE; KIDNEY DYSPLASIA; KIDNEY FAILURE; LABORATORY TEST; LACTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MASS SCREENING; MATERNAL HYPERTENSION; MEDICAL SOCIETY; MONOTHERAPY; MORNING STIFFNESS; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OLIGOHYDRAMNIOS; OLIGOSPERMIA; OSTEOPOROSIS; PAIN ASSESSMENT; PARESTHESIA; PATENT DUCTUS ARTERIOSUS; PATIENT COUNSELING; PATIENT EDUCATION; PHOTOSENSITIVITY; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PNEUMONIA; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; REHABILITATION CARE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPSIS; SEROLOGY; SIDE EFFECT; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TINNITUS; TREMOR; TUBERCULOSIS;

EID: 84992229908     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0973-3698(10)60373-1     Document Type: Article

References (67)

1. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 1993; 13: 131-4.
2. Chopra A, Patil J, Billampelly V, Relwani J, Tandale HS. Prevalence of Rheumatic diseases in a rural population in Western India: A WHO-ILAR COPCORD Study. J Assoc Physicians India 2001; 49:240-6.
3. Indian guidlines for the management of rheumatoid arthritis. J Assoc Physicians India 2002; 50: 1207-18.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finny C, Curtis JR et al. American College of Rheumatology 2008 Recommendation for the use of non biologic and biologic disease modifying anti rheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
6. Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
7. Kumar A, Malaviya AN, Pandhi A, Singh R, Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis. Rheumatology 2002; 41: 1457-9.
8. Chopra A, Lavin P, Palwardhan B, Chitre D. Randomized double blind trial of an Ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol 2000; 27: 1365-72.
9. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; Vol. 12: No. 11.
10. Rostom A, Dube C, Jolicoeur E, Boucher M, Joyce J. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 2004. Technology Overview No. 12. URL: http://www.ccohta.ca/publications/ pdf/261_gastro_to_e.pdf. Accessed 7 May 2004.
11. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, el al, Cardiovascular events associated with rofecoxib in a coloreetal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
12. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
13. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
14. European Medicines Agency. European Medicines Agency update on non-selective NSAIDs. URL: http://www.emea.eu.int/pdfs/human/press/pr/ 29896 405en.pdf. Accessed 31 August 2006.
15. Dunn MJ. Are COX-2 selective inhibitors nephrotoxic? Am J Kidney Dis 2000; 35: 976-7.
16. Kiwan JR, Bijisma JW, Boers M, Shea BJ. Effects of glucocorticoids on the radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1: CD 006356.
17. Buttgereit E Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371(9608): 205-14.
18. Combe B, Landewé R, Lukas C, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 5 Jan.
19. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). Rheumatology 2006, 13 Jul 1-16.
20. SIGN. Management of Early Rheumatoid Arthritis; 2000 December.
21. Emery P, Suarez-Almazor M. Rheumatoid arthritis. Clinical Evidence 2003; 10: 1454-76.
22. Choy EHS, Smith C, Dore CJ, et al. A meta-analysis of the efficacy and toxicity of combining diseasemodifying antirheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005; 44: 1414-21.
23. Misra R, Amin S, Joshi VR, et al. Open label evaluation of the efficacy and safety of etanercept in rheumatoid arthritis. J Ind Rheumatol Assoc 2005; 13: 131-4.
24. British Society for Rheumatology. Guidelines for prescribing TNF-blockers in adults with rheumatoid arthritis. London: British Society for Rheumatology, 2001.
25. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept and Infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62(suppl 2): ii13-6.
26. Van der Bijl AE, Breedveld FC, Antoni C et al. Infliximab failures in rheumatoid arthritis can be successfully treated with Adalimumab (Humira). Ann Rheum Dis 2004; 63(suppl 1): 264.
27. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
28. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
29. British Society for Rheumatology. Vaccinations in the immunocompromised person - guidelines for the patient taking immunosuppressants, steroids and the new biologic therapies. London: British Society for Rheumatology, 2002.
30. Handa R, Misra R, Chaturvedi VP, Pispati PK, Rao URK, Joshi VR. Guidelines for tuberculosis prophylaxis during anti tumor necrosis factor APLAR. J Rheumatol 2606; 9: 181-3.
31. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002; 61: 251-3.
32. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
33. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
34. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793 806.
35. Keystone E, Emery P, Peterfy CD, et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX Study) [abstract]. Ann Rheum Dis 2006; 65 Suppl II.
36. Golding A, Haque JU, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin N Am 2007; 33:319-43.
37. Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996; 14: 69-77.
38. Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone excretion in human milk. J Pediatr 1985; 1061008-11. 342.
39. Chambers CD, Tutuncu ZN, Johnson D, et al. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006; 82: 15-24.
40. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003; 7:401-13.
41. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489-98.
42. Brok J, Mellerup MT, Krogsgaard K, et al. Glucocorticosteroids for viral hepatitis C. Coehrane Database Syst Rev 2004; 2: CD002904.
43. Thong BY, Koh ET, Chng HH, et al. Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases. Ann Acad Med Singapore 2007; 36: 100-5.
44. Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363-8.
45. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008.
46. Galeazzi M, Bellisai F, Manganelli S, et al, Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006; 5: 493-8.
47. Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007; 16: 65-73.
48. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin N Am 2007; 33: 57-70.
49. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin N Am 2007; 33: 197-217.
50. Bressolle F, Bologna C, Kinowski JM, et al. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol 1997; 24: 1903-9.
51. Wilkieson CA, Madhok R, Hunter JA, et al. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med 1993; 86: 501-5.
52. Chan J, Sanders DC, Du L, et al. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38: 1206-11.
53. Bijlsma JWJ. Analgesia and the patient with osteoarthritis. Am J Ther 2002; 9: 189-97.
54. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
55. Lockie LM, Gomez E, Smith DM. Low dose adrenocorticosteroids in the management of elderly patients with rheumatoid arthrtitis. Semin Arthritis Rheum 1983; 12: 373-81.
56. van Schaardenburg D, Valkeme R, Dijkmans BAC, et al. Prednisone for elderly-onset rheumatoid arthritis: efficacy and bone mass at one year. Arthritis Rheum 1993; 36: S269.
57. Swarup A, Sachdeva N, Schumacher HR. Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol 2004; 10: 190-204.
58. Schusziarra V, Ziekursch V, Schlamp R, et al. Pharmacokinetics of azathioprine under hemodialysis, Int J Clin Pharmacol Biopharm 1976; 14: 298-302.
59. Aronoff GR, Brier M. Prescribing drugs in renal disease. In: Brenner BM, ed. Brenner and Rector's The Kidney, Vol. 2. 7th edn. Philadelphia: Saunders 2004: 2850-70.
60. Beaman JM, Hackett LP, Luxton G, et al. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother 2002; 36: 75-7.
61. Ortiz-Santamaria V, Valls-Roc M, Sanmari M, et al. Anti-TNF treatment in secondary amyloidosis. Rheumatology 2003; 42: 1425-6.
62. Wasko MCM, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187-93.
63. Pedersen B, Saltin B. Evidence for prescribing exercise as therapy in chronic disease, Scand J Med Sci Sports 2006; 1 (suppl 16): 3-63.
64. Geytenbeek J. Evidence for effective hydrotherapy. Physiotherapy 2002; 88: 514-29.
65. Casimiro L, et al. Therapeutic ultrasound for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002(3): p. CD003787.
66. Robinson V, et al. Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2002: p. CD002826.
67. Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand. Cochrane Database Syst Rev 2003: p. CD004377.